Flolan Scleroderma PH Claim Expands Potential Patient Rolls By Over 30,000
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The approved patient population for Glaxo Wellcome’s Flolan is expanding by at least 30,000 with the drug’s recent clearance for use in scleroderma patients with pulmonary hypertension, according to Glaxo figures.